Therapeutic Drug Monitoring in IBD
Therapeutic monoclonal antibodies such as TNFα and Integrin blockers have revolutionised the treatment of Inflammatory Bowel Disease, by reducing inflammation, tissue damage and need for surgery, whilst improving mucosal function and quality the of life for sufferers. However monoclonal antibody drugs are recombinant proteins that can induce humoral immune responses and so there are a number of challenges to overcome in the successful treatment of advanced inflammatory diseases.
Being able to determine which patients are likely to benefit from biological therapy and navigate the risks associated with adverse drug reactions (ADRs), primary non-response(PNR) and loss of response (LOR) could be enormously beneficial to patients, providers and payers.
BIOHIT HealthCare has specialised in the therapeutic drug monitoring market for 10 years and its assays have been used to generate some of the UKs most valuable data in the management of IBD.